Assessment and monitoring of biologic drug adverse events in patients with psoriasis

Tessa Hanley
Marc Handford
Dawn Lavery
Zenas ZN Yiu
Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester, UK

Background: Current treatment guidelines for biologic therapies in psoriasis differ in their recommendation for the monitoring of adverse events.

Objective: The aim of this paper was to draw together evidence from the currently available guidelines as a summary of how biologics licensed for the treatment of psoriasis should be monitored for adverse events.

Methods: The MEDLINE database was searched to identify the current literature on the safety and screening guidance associated with infliximab, etanercept, adalimumab, ustekinumab, and secukinumab.

Limitations: This study was limited by the lack of data evaluating monitoring in patients with psoriasis undergoing treatment with a biologic therapy.

Results: This review of the current literature highlights that there are areas of routine screening, which are recommended in current practice, which require further evidence to investigate its true utility.

Conclusion: Most screening and monitoring tests performed routinely in clinical practice are supported by minimal clinical evidence, highlighting the need for more studies to evaluate the role and value of the different modalities of screening and monitoring for adverse events in those with psoriasis receiving treatment with biologic therapies.

Keywords: biologics, monitoring, psoriasis, screening, safety

Background
Psoriasis is a common, chronic, inflammatory skin disease affecting between 1% and 3% of the world population. It is characterized by erythematous pruritic plaques and associated with a significant impairment in the quality of life akin to other chronic medical conditions, eg, diabetes. Psoriasis is also associated with a number of other chronic conditions, including cardiovascular disease, depression, and metabolic syndrome, while ~25% of patients also suffer from psoriatic arthritis. Management of psoriasis should therefore be holistic, timely, and effective and provide long-term disease control.

Traditional standard systemic therapies for the treatment of moderate-to-severe psoriasis include methotrexate, ciclosporin, acitretin, and fumaric acid esters. These treatments can be ineffective and are associated with long-term adverse effects.

The biologic therapies offer a potent treatment alternative to patients with moderate-to-severe psoriasis. They block specific cytokine pathways pertinent to the pathogenesis of psoriasis, and there is a substantial body of evidence to support the use of these agents. The National Institute for Health and Care Excellence (NICE),
a national guidance body in the UK, has now recommended five biologic therapies for the treatment of moderate-to-severe psoriasis, which include etanercept, infliximab, adalimumab, and ustekinumab, with secukinumab that was recommended for severe plaque psoriasis as of July 2015.1

Although the efficacy of the biologic therapies has been well established through clinical trial data, there is a significant uncertainty regarding the incidence and prevalence of short- and long-term adverse effects of these drugs and how they should be monitored. This is due to the fact that most of the published clinical trials have insufficient sample sizes to detect rare adverse events and/or were conducted for a short period of time. Trial extensions were often conducted without a control arm, making it difficult to assess the incidence of adverse events of these treatments in the moderate-to-severe psoriasis population. In addition, most trials excluded patients with significant comorbidities resulting in a poor external validity for the safety profile of these drugs in the real-world clinic.6 The potential for any drug to produce rare but significant adverse effects was demonstrated by the experience with efalizumab, which was withdrawn from the market in 2009 by the European Medicines Agency following its association with progressive multifocal leukoencephalopathy through the analysis of postmarketing pharmacovigilance data.7,8 The safety profile of biologic therapies, therefore, would be best evaluated through the interrogation of observational data, such as prospectively established treatment registries. In the UK, NICE recommends that all patients starting treatment with biologics are invited to participate in the British Association of Dermatologists Biologic Interventions Register (BADBIR).9 The BADBIR is a prospective pharmacovigilance study setup to assess the long-term safety of biologic treatments for psoriasis, comparing patients on biologic therapies with a similar patient control group on conventional systemic agents.9,10

Understanding the risks of adverse events of biologic therapies is crucial for consent, safe prescribing, and monitoring of these drugs.

Objective

The aim of this paper was to review the current literature surrounding the potential adverse effects of the five biologics commonly used in the treatment of moderate-to-severe psoriasis and draw together evidence from international guidelines as a summary of how these drugs should be monitored.

Methods

The MEDLINE database was searched for articles pertaining to biologic agents in the treatment of psoriasis/pсорiatic arthritis. Key search terms included: psoriasis/psoriatic arthritis, safety, screening, and biologics (search included trade names). English language articles published between 2000 and 2015 were reviewed, whereas single case reports were discarded. Articles identified within citations from reviewed articles were also reviewed for inclusion.

Introduction

The current guidance on screening and monitoring from the British Association of Dermatologists (BAD), the European Academy of Dermatology and Venereology (EADV), and the American Academy of Dermatology (AAD) is highlighted together in Table 1. The guidance on each separate category is reviewed in detail with a following discussion, and the conclusions of which are drawn together at the end of the paper.

Overview of serious adverse effects of biologics

Serious infection

Tumor necrosis factor (TNF)-α is needed for formation and maintenance of granulomas; its inhibition can therefore increase the risk of infections such as tuberculosis (TB). TNF-α is also involved in macrophage activation, macrophage differentiation, and phagosome formation, therefore, holding a critical role in the clearance of intracellular pathogens. Furthermore, TNF inhibitors can cause neutropenia and increasing risk of bacterial infection and reduce the immune response to viral pathogens.11

Data surrounding serious infection in patients with psoriasis are limited. The psoriasis longitudinal assessment and registry, which is a large, pharmacovigilance registry based in the USA and Europe for patients with psoriasis, run by the drug company Janssen Cilag contains data from 12,095 patients.12 When looking at TNF inhibitors and ustekinumab combined, the risk of developing a serious infection was determined to be 1.45 per 100 patient-years, compared with rates of 1.05 and 1.28 per 100 patient-years in non-methotrexate/nonbiologics and methotrexate/nonbiologic cohorts, respectively. Adalimumab and infliximab therapy was associated with significantly higher incidence of serious infections than other biologics (1.97 and 2.49 per 100 patient-years, respectively), while ustekinumab had the most favorable results with rates of 0.83 serious infections per 100 patient-years. The analysis of data, after adjustment for probable confounders, found that exposure to infliximab or adalimumab was independent risk factors for serious infection as compared with systemic retinoid therapy and/
Table 1  Current guidelines on screening and monitoring of adverse events in patients taking biologics

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TNF inhibitors</strong></td>
<td><strong>TNF inhibitors</strong></td>
<td><strong>TNF inhibitors/ustekinumab</strong></td>
</tr>
<tr>
<td><strong>General infection</strong></td>
<td><strong>TNF inhibitors contraindicated in patients with active, serious infection</strong></td>
<td>Recurrent or severe infections are a relative contraindication for use of all TNF inhibitors</td>
</tr>
<tr>
<td>Pretreatment: All patients on biologics should be warned about risk factors for Salmonella and Listeria</td>
<td>Pretreatment: No specific guidance issued</td>
<td>Pretreatment: History and examination for evidence of infection</td>
</tr>
<tr>
<td>During treatment: Patients should be monitored for early signs and symptoms of infection throughout the treatment. 3–6 monthly intervals are advised</td>
<td>During treatment: “Periodic” history and examination are recommended</td>
<td>During treatment: Clinical assessment for risk factors of serious infection – frequency of assessment is not stated</td>
</tr>
<tr>
<td><strong>TB infection</strong></td>
<td><strong>Active TB is a contraindication to therapy</strong></td>
<td><strong>Active TB is a contraindication to therapy</strong></td>
</tr>
<tr>
<td>Pretreatment: All patients should be assessed for active or latent TB before starting biologic therapy – CXR and mantoux test (if no immunosuppression in the last 3 months)</td>
<td>Pretreatment: TB testing (tuberculin skin test) should be performed on all patients before treatment</td>
<td>Pretreatment: Prescreening guidelines recommend anamnesis, a CXR, tuberculin skin test, and QuantiFERON</td>
</tr>
<tr>
<td>CXR and TB ELISpot/QuantiFERON if immunosuppressed. Refer all patients with a history of previously treated TB</td>
<td>Institutional workers/frequent travelers need repeat screening at “appropriate” intervals. CXR is not indicated</td>
<td><strong>Contraindicated in active infections</strong></td>
</tr>
<tr>
<td>Those with latent TB should receive treatment prior to initiating therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>During treatment: Consider risk factors for tuberculosis before treatment and at 3–6 monthly intervals</td>
<td>During treatment: Yearly TST testing</td>
<td><strong>Contraindicated in active infections</strong></td>
</tr>
<tr>
<td>Annual IGRA if following assessment patient felt to have been exposed to TB</td>
<td>Institutional workers/frequent travelers need repeat screening at “appropriate” intervals</td>
<td></td>
</tr>
<tr>
<td><strong>Hepatitis (B and C)</strong></td>
<td>Pretreatment: Insufficient evidence to justify use of TNF inhibitors in patients with chronic, potentially harmful viral infections (HIV/HBV/HCV/herpes) – needs a case-by-case assessment</td>
<td>Pretreatment: With regard to prior/current hepatitis B infection and current chronic hepatitis C infection – treatment guidelines advise consultation with gastroenterologist or hepatologist before initiating the treatment</td>
</tr>
<tr>
<td>Pretreatment: Screen for HBV in appropriate clinical setting (reactivation of HBV after TNF inhibitors commenced has been reported). Consultation with liver specialist advised when considering biologics in patients with concomitant HCV</td>
<td>Guidelines also give drug-specific guidance as follows: 1. Adalimumab and infliximab – active chronic HBV is an absolute contraindication to use; HCV is a relative contraindication to use</td>
<td></td>
</tr>
<tr>
<td>During treatment: In those with HCV, periodic assessment of viral load</td>
<td></td>
<td>2. Etanercept – chronic active HBV and HCV are relative contraindications to use and antiretroviral drugs are recommended if biologic therapy is to be initiated</td>
</tr>
<tr>
<td>Hepatitis B – periodic assessment for those at risk</td>
<td>During treatment: No specific guidance issued</td>
<td><strong>Treatment guidelines advise consultation with gastroenterologist or hepatologist before initiating the treatment</strong></td>
</tr>
<tr>
<td><strong>Cardiovascular disease</strong></td>
<td>Pretreatment: Therapy contraindicated in NYHA class III/IV</td>
<td>Pretreatment: History and examination for evidence of congestive heart failure</td>
</tr>
<tr>
<td>Pretreatment: Therapy contraindicated in NYHA class III/IV</td>
<td>Pretreatment: Therapy contraindicated in NYHA class III/IV</td>
<td>NYHA class III/IV is a contraindication for all TNF inhibitors</td>
</tr>
<tr>
<td>Echo if well compensated NYHA class I/II – if LVEF &lt;50% consider avoiding biologic therapy</td>
<td>Echo if well compensated NYHA class I/II – if LVEF &lt;50% consider avoiding biologic therapy</td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TNF inhibitors</strong></td>
<td><strong>TNF inhibitors</strong></td>
<td><strong>TNF inhibitors/ustekinumab</strong></td>
</tr>
<tr>
<td>During treatment: Monitoring at 3–6 months</td>
<td>During treatment: “Periodic” history and examination are recommended</td>
<td>During treatment: Clinical assessment for signs of congestive heart failure – frequency of assessment not stated</td>
</tr>
<tr>
<td><strong>Neurological disease</strong></td>
<td>Pretreatment: Contraindicated in patients with MS or other demyelinating disease</td>
<td>TNF inhibitors are not recommended in patients with MS or other demyelinating disease</td>
</tr>
<tr>
<td>Use in caution in patients with first-degree relative with demyelinating disease</td>
<td>Evidence “strongly suggests” avoidance in patients with first-degree relatives with MS</td>
<td>Use TNF inhibitors with caution in patients with a first-degree relative with a demyelinating disease</td>
</tr>
<tr>
<td>During treatment: Withdraw drug if symptoms are suggestive of demyelination Monitoring at 3–6 months</td>
<td>During treatment: “Periodic” history and examination are recommended</td>
<td>During treatment: History and examination for evidence of neurological symptoms</td>
</tr>
<tr>
<td><strong>Malignancy</strong></td>
<td>Pretreatment: Ensure concordant with national screening programs</td>
<td>During treatment: Clinical assessment for neurological symptoms – frequency of assessment not stated</td>
</tr>
<tr>
<td>Biologic therapy is relatively contraindicated in patients with a history of prior therapy with PUVA (&gt;200) and/or UVB (&gt;350) Pretreatment: Use in caution in patients with first-degree relative with demyelinating disease</td>
<td>Take history of past or present malignancy – TNF inhibitors are relatively contraindicated in patients with a malignancy in the past 5 years</td>
<td><strong>Can be used in patients with coexisting neurological disease</strong></td>
</tr>
<tr>
<td>During treatment: Monitor every 3 months</td>
<td>During treatment: “Periodic” history and examination are recommended</td>
<td>PUVA (&gt;200 treatments) is a relative contraindication to treatment with all TNF inhibitors</td>
</tr>
<tr>
<td><strong>Vaccinations</strong></td>
<td>Pretreatment: Carefully consider use in patients with history of malignancy (particularly lymphoma) Consider potential risk of T-cell lymphoma, melanoma, and nonmelanoma skin cancer</td>
<td>Malignancies and lymphoproliferative disorders are a relative contraindication for all TNF inhibitors – in patients with current cancer or cancer in the past 5 years, treatment decision has to be made on a case-by-case basis following discussion with a cancer specialist</td>
</tr>
<tr>
<td>Pretreatment: Vaccination should be reviewed and brought up prior to initiation of biologic therapy with reference to the Department of Health Guidance Patients should not receive live or attenuated vaccines &lt;2 weeks before of 6 months after discontinuation of therapy Inactivated vaccines are safe to administer concurrently, but ideally should be given 2 weeks prior to starting therapy for an optimal immune response</td>
<td>Pretreatment: Standard vaccinations including pneumococcal, hepatitis A and B, influenza, and tetanus are recommended prior to initiation of therapy Once the treatment has begun, live vaccines and live attenuated vaccines are to be avoided in all circumstances</td>
<td>Pretreatment: History and examination focusing on evidence of malignancy During treatment: Clinical assessment focusing on lymphadenopathy, malignancies (especially skin cancer), and premalignant lesions – frequency of assessment not stated</td>
</tr>
<tr>
<td>During treatment: Patients should be advised to receive the pneumococcal and annual influenza vaccine during treatment</td>
<td>During treatment: Physicians should consider the advantages and disadvantages of killed virus vaccines such as influenza</td>
<td>Pretreatment: All recommended vaccination should be given prior to any systemic therapy. In general, common vaccinations with nonlive vaccines are safe during treatment with all drugs Live vaccines and are mostly contraindicated Vaccination status for hepatitis A and B is important and primary vaccination and/or boosting should be performed before systemic treatment initiation</td>
</tr>
<tr>
<td><strong>Laboratory testing</strong></td>
<td>Pretreatment: FBC, LFTs, and hepatitis profile – including hepatitis B and hepatitis C serology</td>
<td>During treatment: During therapy with all systemic agents annual influenza vaccination is recommended</td>
</tr>
<tr>
<td>Pretreatment: FBC, U&amp;E, LFTs, hepatitis B/hepatitis C/HIV serology, autoantibodies including ANA and anti-dsDNA Beta-HcG in females if believed to be at risk of pregnancy</td>
<td>Pretreatment: FBC, U&amp;E, LFTs, CRP, hepatitis B/hepatitis C/HIV serology, urinalysis, urine beta-HcG (females)</td>
<td>(Continued)</td>
</tr>
</tbody>
</table>
Table 1 (Continued)


| TNF inhibitors | TNF inhibitors | TNF inhibitors/ustekinumab

During treatment: Repeat FBC, U&E, and LFTs at 3 months and 6 months. Repeat hepatitis B and HIV serology “periodically” in those at risk. Autoantibodies if development of autoimmune disease

During treatment: “Periodic” FBC and LFTs

During treatment: Etanercept and adalimumab = FBC, U&E, LFTs, and urinalysis at 4 weeks, 12 weeks, and every 3–6 months thereafter. Infliximab = repeat FBC, U&E, LFTs, and urinalysis at 4 weeks, 12 weeks, and prior to each infusion

Note: **Guidance relating to ustekinumab.

Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IGRA, interferon gamma release assay; MS, multiple sclerosis; PUVA, 8-methoxypsoralen-ultraviolet A; TB, tuberculosis; TNF, tumor necrosis factor; TST, tuberculin skin test; UVB, ultraviolet B; NYHA, New York Heart Association; CXR, chest X-ray; FBC, full blood count; U&E, urea and electrolytes; HcG, human chorionic gonadotropin; ANA, anti-nuclear antibodies.

or phototherapy, with hazard ratios of 2.51 (95% confidence interval (CI): 1.45–4.33; \( P<0.001 \)) and 2.13 (95% CI: 1.33–3.41; \( P=0.002 \)), respectively. Additional risk factors were found to be increased age and a previous history of serious infection.\(^{12}\)

A 2012 study by Reich et al evaluated 4 years of pooled safety clinical trial data of ustekinumab in patients with moderate-to-severe psoriasis found that rates of serious infection for doses of ustekinumab (45 mg and 90 mg) were consistent with the incidence of serious infection in the general population. Cumulative rates per 100 patient-years were 0.8 and 1.32 for doses of 45 mg and 90 mg, respectively, concurring with the psoriasis longitudinal assessment and registry results.\(^{13}\)

Two Phase III, double-blinded trials assessed the safety of secukinumab over a 52-week period. A total of 738 patients were randomly assigned to the Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis (ERASURE) study and 1,306 patients to the Full-Year Investigative Examination of Secukinumab vs Etanercept Using Two Dosing Regimens to Determine Efficacy in Psoriasis (FIXTURE) study. Patients were assigned to secukinumab 300 mg, 150 mg, or placebo, and patients in the FIXTURE study are also assigned to another group of etanercept 50 mg. The ERASURE study found serious infection rates to be 1.0, 0.7, and 1.5 per 100 patient-years for the 300 mg, 150 mg, and placebo groups, respectively. The FIXTURE study showed serious infection rates to be 1.5, 0.6, and 0.3 and 1.2 per 100 patient-years for the 300 mg, 150 mg, and placebo and etanercept groups, respectively.\(^{14}\)

Guidelines for assessment and monitoring

Given the mode of action of the biologic therapies, patients are at an increased theoretical risk of infection. Furthermore, there is literature demonstrating an increased risk of infection with adalimumab and infliximab compared with retinoid therapy and/or phototherapy. All patients receiving treatment with a biologic therapy, therefore, need to be actively and routinely monitored for evidence of infection. Current guidelines offer no consensus on how often this should be.

Tuberculosis

TNF inhibitor treatment has been associated with an increased risk of TB reactivation.\(^{7}\) The majority of the data supporting this come from rheumatology studies and registries; however, differences in underlying primary pathology and comorbidities mean that inferring results to patients with psoriasis is difficult.

Sánchez-Moya et al published an analysis of the Spanish registry for systemic biological and nonbiological treatments in psoriasis. He identified 793 patients receiving biologic therapy for psoriasis. Overall follow-up was 3,720 patient-years. Of the 793 patients, 163 (20.5%) tested positive for latent TB prior to the initiation of therapy. Of the patients with latent TB infection, there was an incidence of active infection of 145 cases per 100,000 patient-years compared with a control group in which there were no cases of active TB infection (95% CI: 54–389).\(^{15}\) These data support the findings of Sánchez-Moya and Dauden and Ergun et al who showed modest TB reactivation rates of 1.08% (sample size: 370) and 2.38% (sample size: 42), respectively, in patients on anti-TNF agents. Neither study had a control group.\(^{16,17}\)

Ustekinumab is a fully human monoclonal antibody that targets interleukin (IL)-12 and IL-23. It binds to the p40 subunit disrupting the inflammatory cascade implicated in the pathogenesis of psoriasis.\(^{18}\) The IL-12 pathway is important in regulating immunity to mycobacterium
TB, and it is therefore reassuring to note that data from 3,177 patients with psoriasis across five Phase III trials of ustekinumab (45 mg or 90 mg) found that in patients with a positive tuberculin skin test (TST) or quantiFERON gamma assay there were no cases of latent TB reactivation in those having taken isoniazid prophylaxis.\(^9\) The analysis of prospective registries in this regard is critical to establishing the true risk of acquired or reactivated TB in patients on ustekinumab.

Secukinumab is a fully human anti-IL-17A monoclonal antibody.\(^3\) The analysis of pooled data from Phase III clinical trials has shown no evidence of reactivation of previous or latent TB compared with placebo.\(^20\)

It should be noted that clinical TB infection has been shown to vary between the different biologic agents. This has been demonstrated by the examination of case reports to the US Food and Drug Administration, which found the median time between the initiation of therapy and evidence of clinical infection is 3 months, 4–6 months, and 11.5 months for infliximab (n=70), adalimumab (n=15), and etanercept (n=25), respectively. It should be noted that the majority of these infections are the reactivation of latent TB infection.\(^3,21–23\)

Guidelines for assessment and monitoring

Table 1 highlights the current guidelines with respect to the assessment of TB prior to biologic therapy and monitoring during therapy. As secukinumab is new to the market, there were no specific guidelines at the time of publication. However, NICE concluded that secukinumab did not appear to be associated with adverse events not already known for biological treatments in general, suggesting that the same precautions should be taken pre-therapy as with other biologic therapies.\(^24\)

There are two commonly used screening tests for exposure to TB—the TST and the interferon gamma release assay (IGRA), marketed as QuantiFERON gold. BAD guidelines, published 6 years ago, suggest using the IGRA only in immunosuppressed patients. However, studies that have compared the two methods of screening have shown the IGRA to have higher sensitivity and specificity.\(^5,22\) A 2008 meta-analysis of studies comparing TST vs IGRA for detecting latent TB across a variety of patient populations determined that TST sensitivity was poorly concordant across studies with a pooled estimate of 77%. Pooled estimate of specificity was 97% in non-Bacillus Calmette–Guérin (BCG)-vaccinated populations but only 77% in BCG-vaccinated populations. The IGRA had a pooled sensitivity of 76% and a specificity of 99% in non-BCG-vaccinated populations and 96% in BCG-vaccinated populations.\(^26\)

Few studies have examined how the presence of psoriasis affects the IGRA. Garcovich et al used the IGRA as gold standard and compared its clinical correlation with TST in patients with psoriasis before biologic therapy, at 6 months and 12 months. Results showed agreement to be moderate (K=0.408) at screening, good (K=0.734) at 6 months, and fair (0.328) at 12 months.\(^27\) A 2009 retrospective study of 50 patients with psoriasis found the agreement between the IGRA and TST to be fair (K=0.33).\(^28\)

One explanation for poor agreement of TST with IGRA in patients with psoriasis is that a skin test performed on patient with an underlying inflammatory skin condition is more likely to give a false-positive result.\(^25\)

Screening and monitoring for TB are essential, given the underlying mechanisms of action of the different biologic therapies. All clinicians must be aware of the risk of the reactivation of latent TB, despite initial treatment with anti-TB therapy, always maintaining a high level of suspicion, particularly as the presentation is often atypical.\(^5\)

Current recommendations for pretreatment screening are highlighted in Table 1. The main disparity between guidelines is regarding annual screening during the treatment. The BAD advises IGRA testing if a patient has been at high risk of TB exposure, AAD recommends yearly TST testing as standard with more frequent testing in high-risk groups, and EADV recommends both TST and IGRA testing on a yearly basis.

The EADV rationale for dual testing is that patients on biologics will have a degree of immunosuppression, therefore increasing the risk of false negatives in both the IGRA and TST as they both require a T-cell immune response. Dual testing is therefore a “belt-and-braces” approach to screening.\(^29\)

Given that evidence demonstrates IGRA to be the superior test it would seem the most appropriate pretreatment and monitoring test for TB infection. This is supported by NICE guidelines for TB, which state that the IGRA as a standalone test is sufficient in those with immunosuppression. Furthermore, in countries with high BCG vaccination rates, false positives in TST are more likely and could lead to inappropriate, prolonged courses of anti-TB medications.\(^30\) Annual screening is the current consensus with regular patient reviews to assess possible exposures. The authors’ opinion is for both pretreatment and annual IGRA testing. Patients with latent TB should be treated with chemoprophylaxis, eg, 6 months of isoniazid which is the NICE-recommended...
treatment. The consensus is the treatment should be for 1 month prior to the commencement of immunosuppression, but no firm data exist to support this contention.\textsuperscript{31}

**Human immunodeficiency virus**

There are a few case reports regarding human immunodeficiency virus (HIV) and treatment with TNF inhibitors. From the limited data available, treatment with TNF inhibitors did not increase viral load.\textsuperscript{32}

**Hepatitis**

**Hepatitis B**

A total of 350 million patients are estimated to have chronic hepatitis B virus (HBV) infection worldwide.\textsuperscript{33} After inoculation of the virus, there can be four possible disease states: acute, chronic, occult, and resolved. The risk of reactivation of HBV is variable depending on whether a patient's hepatitis B is:

- chronic (HBsAg and HBeAb positive, HBsAb negative, and subclassified into active or inactive carriers depending on viral load),
- occult (HBsAg negative, HBeAb positive), or
- resolved (HBsAb positive).\textsuperscript{34,35}

A 2011 analysis of hepatitis B reactivation in patients taking TNF inhibitors for various autoimmune diseases reported a reactivation rate of 39% in patients with chronic hepatitis B and a reactivation rate of only 5% in patients with occult hepatitis B. The study also highlighted the reduced rates of reactivation in patients taking antiviral therapy.\textsuperscript{36}

A small retrospective analysis looking at the reactivation of hepatitis B in 62 occult carriers undergoing treatment with either etanercept, infliximab, or adalimumab for psoriasis did not observe any signs of HBV reactivation. In one patient, there was a reappearance of HBsAg after 10 months of discontinuation from the previous course of treatment. Biological therapy was reintroduced in association with antiretroviral therapy with no adverse events occurring.\textsuperscript{37}

These findings are supported by a 2015 retrospective analysis by Sanz-Bueno et al,\textsuperscript{22} which identified 20 patients who were treated for psoriasis with a biologic agent (TNF inhibitor or ustekinumab) and had evidence of prior infection with hepatitis B (defined as the presence of anti-HBc, the absence of HBsAg, and the presence or absence of anti-HBs) and assessed the cases for evidence of HBV reactivation. Hepatitis B reactivation was defined as the detection of HBV DNA in blood ± conversion to HBsAg+, and it was found that over a median 40-month follow-up there were no cases of reactivation of HBV despite none of the patients receiving chemoprophylaxis. This study combined its data with data from other studies of patients with psoriasis with past HBV infection and concluded that in patients with prior hepatitis B (but no evidence of chronic carriage) there is a maximum estimated risk of reactivation of 2.7 per 100 patient-years for a mean follow-up of 30 months and advised regular monitoring of alanine transaminase (ALT) and HBV viral load in this cohort of patients. Monitoring intervals were not commented on.\textsuperscript{38}

**Hepatitis C**

The review of Pompili et al assessed the effect of TNF inhibitors over a median of 1.2 years in 216 patients with chronic hepatitis C, suffering various autoimmune conditions including psoriasis, where three of whom had withdrawn the treatment on account of deteriorating hepatic function.\textsuperscript{39}

Data specifically related to psoriasis are sparse. A 2013 retrospective study of 15 chronic hepatitis C sufferers treated for psoriatic arthritis with TNF inhibitors showed no worsening of viral load or liver markers over a 12-month follow-up period.\textsuperscript{40}

There is limited evidence regarding the safety of ustekinumab treatment in patients with psoriasis and concomitant HBV and hepatitis C virus infection. In a small retrospective, multicentre study of 25 patients with concurrent hepatitis C (20 patients) and hepatitis B infection (five patients), four patients underwent treatment with ustekinumab. In those with hepatitis B infection, all of which were being treated with antiviral therapy, no patients had significant changes in their viral load. Furthermore, the patients with hepatitis C infection receiving treatment with ustekinumab also had no significant changes in their viral load or liver function tests.\textsuperscript{41}

There are no available data with which to draw conclusions about the safety of secukinumab for the treatment of patients with psoriasis who have hepatitis B or C, nor the need for hepatitis screening.

**Guidelines for assessment and monitoring**

All guidelines support performing a hepatitis panel prior to the treatment. HIV screening was also supported by the BAD and EADV but not by the AAD. The evidence is limited to small study populations, but particularly for hepatitis B there is evidence to support prescreening. The risk of reactivation in patients with hepatitis B depends on a number of factors including whether patients are active/inactive/occult carriers, the number of comorbidities, and use of immunosuppression. However, there is no doubt that the risk exists and should be considered before starting the treatment with TNF inhibitor.
therapy. Consultation with a hepatologist would be advised prior to initiating the treatment.

Given that data on ustekinumab are minimal, it would be advisable to follow the same screening guidance as for the TNF inhibitors.

New EADV guidelines state infliximab and adalimumab are absolutely contraindicated in patients with chronic hepatitis B but that etanercept is only relatively contraindicated. The review of cited literature in the EADV guidelines as well as independent literature search has not uncovered any research supporting differing levels of risk between the TNF inhibitors.

Literature suggests that biologic therapy is relatively safe in patients with prior HBV infection (who therefore could be occult carriers) but advises monitoring of ALT and HBV viral load to identify seroconversion. Optimum screening intervals have yet to be determined.

Cardiovascular disease
Ryan et al published a meta-analysis in 2011 focusing on the incidence of cardiovascular disease in patients treated with TNF inhibitors or ustekinumab for psoriasis. A total of 22 randomized controlled trials (RCTs) were identified with a combined patient cohort of 10,183 patients. The primary outcome measure of the meta-analysis was the incidence of Major Adverse Cardiovascular Events (MACE), defined as one of the following: myocardial infarction, cerebrovascular accident, or cardiovascular death. The meta-analysis did not find any association between the use of TNF inhibitors or ustekinumab and increased risk of MACE. Further research by Gottlieb et al and Hugh et al supported these findings, reporting no increased risk of MACE with biologics when compared against patients with psoriasis receiving nonbiologic therapies.

Tzellos et al conducted a meta-analysis looking at the anti-IL12–23s (ustekinumab and briakinumab) and the number of MACEs. Nine RCTs were identified: five using ustekinumab as the intervention and four using briakinumab. No individual RCT showed a statistically significant increased number of MACEs in the treatment arm; however, when all RCTs were analyzed together anti-IL12–23s were found to have a statistically significant increased risk (odds ratio [OR]: 4.23; 95% CI: 1.07–16.75; P=0.04).

Both the secukinumab trials, ERASURE and FIXTURE, recorded the incidence of MACE over a 52-week follow-up period. The reported incidence of MACE per 100 patient-years for secukinumab 300 mg, secukinumab 150 mg, and placebo were 0.7, 0.7, and 0, respectively, in the ERASURE study and 0, 0.4, and 0, respectively, in the FIXTURE study. The statistical significance of these figures was not commented on.

Guidelines for assessment and monitoring
All guidelines recommend that TNF inhibitors are contraindicated in patients with New York Heart Association (NYHA) class III or IV heart failure and advise caution in those with NYHA classification stage I or II disease. The British and American guidelines recommend echocardiography for patients with NYHA I or II heart failure and advise physicians to consider alternatives to biologic therapy if a patient has left ventricular ejection fraction (LVEF) <50%. This guidance is borne out of findings from the 1999 Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial that was conducted to determine whether infliximab would improve outcomes in 150 patients with heart failure with an NYHA classification of III or VI and a left ventricular ejection fraction of <35%. The trial showed increased rates of all-cause mortality or hospitalization due to heart failure compared with placebo in the infliximab 10 mg/kg arm of the trial.

Subsequent studies have failed to show association between TNF inhibitors and worsening of heart failure across a variety of patient groups and data in psoriasis-specific patient groups have shown no such association. There are no trials associating ustekinumab or secukinumab with heart failure. In those with NYHA I or II heart failure, it is likely that benefits of treatment would outweigh risk.

There is no current evidence to support an increased risk of MACE with any of the biologic therapies currently licensed for psoriasis; however, the results of the Tzellos study suggest that further investigation into the risk of MACE with IL12–23 inhibitors would be valuable.

Neurological disease
As of present, pharmacovigilance data have shown no association between TNF inhibitors and demyelinating disease. Current guidance from the BAD recommends avoiding their use in patients with a history of demyelinating disease or in those with a first-degree relative with a history of demyelinating disease, based on numerous case reports of exacerbations of multiple sclerosis (MS) or ne-onset central demyelination.

Initial concerns over the TNF inhibitors arose from a study in 1999 assessing lenercept in MS, which resulted in early deterioration of the MS.
A 2009 Phase II, multicentre, double-blind, placebo-controlled RCT looked at the use of ustekinumab with relapsing remitting MS. This trial demonstrated no evidence of worsening neurological disease.30

Guidelines for assessment and monitoring

The current, conflicting evidence suggests that TNF inhibitors can induce/exacerbate the MS. Given the uncertainty surrounding this link, the suggestion from all three guidelines to avoid TNF inhibitors in patients with MS seems prudent. This position is reinforced by the literature and given that there are alternative biologics (ustekinumab); the risk would be unacceptable. The most recent European guidelines now recommend the use of ustekinumab in concomitant demyelinating conditions.21

Malignancy

The evidence base on which current recommendations for screening in psoriasis patients commencing treatment with biologics in malignancy is limited. Increased rates of tobacco and alcohol use in patients with psoriasis mean that as a group they have higher rates of certain cancers (respiratory tract, digestive tract, urinary tract cancers).51 The same meta-analysis showed a higher risk of squamous cell carcinoma in patients with psoriasis (standardized incidence ratio of 5.3), possibly linked to their exposure to 8-methoxypsoralen-ultraviolet A, ciclosporin, and methotrexate. Patients with psoriasis were also found to be at higher risk of nonmelanoma skin cancer.51

Dommasch et al in a meta-analysis of randomized, placebo-controlled trials, which looked at the risk of malignancy in 6,810 adults with psoriatic disease treated with TNF inhibitors, found no statistically increased risk of cancer, except for nonmelanoma skin cancer.52

Most of the researches into association between TNF inhibitors and cancer are from studies of patients who are treated for rheumatoid arthritis. Although safety may be inferred from such data, it is not ideal to assume that it is applicable to other disease states.

In 2006, Bongartz et al published a meta-analysis of nine RCTs that included data from 3,493 patients with rheumatoid arthritis treated with either infliximab or adalimumab vs placebo and concluded that TNF inhibitors were associated with an increased risk of all cancers (with a large number of the cancers found to be nonmelanoma skin cancer).53

However, subsequently published data from the Swedish and German rheumatology biologic registers,54,55 data collated from 2001 to 2011 by the British Society of Rheumatology and Biologics Registry, and Le Blay et al reported no evidence to suggest that TNF inhibitors confer an increased risk of cancer compared with biologic-naïve patients, except a possible increased risk of nonmelanoma skin cancer in the study by Le Blay et al.56,57 Similarly, the British Rheumatology register showed an increased rate of recurrence of melanoma, but no other cancers in patients taking TNF inhibitors.

There have previously been concerns regarding lymphoma in patients taking TNF inhibitors, but the 2011 Cochrane review into adverse effects of biologics for a number of autoimmune conditions including psoriasis found no evidence associating TNF inhibitors with increased incidence of lymphoma. However, the authors report that given the low numbers of lymphoma cases identified, these results should be interpreted with caution.7

Increased rates of high-grade cervical intraepithelial neoplasia (CIN) and cervical cancer have been seen in females who are immunosuppressed due to HIV infection or because of immunosuppressive therapy post renal transplant.58 The concern that immunosuppression increases the risk of cervical cancer prompted Kim et al to conduct a cohort study comparing 133,333 females with a variety of inflammatory diseases including psoriasis with 533,332 controls.59 Results showed that among 34,665 patients with psoriasis there was a crude incidence rate of high-grade CIN or cervical cancer of 82.2 per 100,000 patient-years compared with rates in the control group of 73.4 per 100,000 patient-years with a hazard ratio of 0.96 (95% CI: 0.73–1.27), therefore showing no statistical significance.59

A 2015 meta-analysis assessing the risk of high-grade CIN or cervical cancer in patients with inflammatory bowel disease receiving immunosuppressive therapy found that immunosuppressed IBD patients had significantly higher rates of high-grade CIN/cervical cancer than females in the general population. This prompted authors to advise increased screening frequency.60

There is a scarcity of literature with regard to CIN/cervical cancer risk in patients with psoriasis and patients taking biologic therapies. Until further evidence is available, patients should be advised to strictly adhere to national screening programs for cervical cancer and to consider human papilloma virus vaccination prior to starting a biologic therapy. In patients with CIN or previous cervical cancer, a gynecological opinion should be sought prior to the decision to start a biologic therapy.

Guidelines for assessment and monitoring

Current guidelines are in agreement that if a patient has had cancer in the last 5 years then TNF-inhibitors and ustekinumab are relatively contraindicated.
Evidence suggests that patients are not at increased risk of any de novo cancer with TNF inhibitors, with the possible exceptions of nonmelanoma skin cancer and melanoma skin cancer. There is evidence that melanoma has increased recurrence rate associated with TNF inhibitors.

BAD guidelines suggest “monitoring,” every 3 months for cancer, although they do not specify what “monitoring” should entail. Evidence would certainly support monitoring for melanoma and nonmelanoma skin cancers in patients receiving biologics, especially in patients with previous such cancers or those considered to be of high risk.

Laboratory testing

BAD, EADV, and AAD guidelines differ significantly in respect of test selection before treatment and retesting frequency during the treatment. van Lümig et al reviewed 162 patients over 5 years receiving either etanercept or adalimumab. Of the 62 patients, 38 (24%) of the adalimumab group and eight (14%) of the etanercept group developed one or more grade 3 (severe/medically significant, but not life-threatening) or grade 4 (life-threatening) laboratory abnormality. Nine percent of patients developed hematological abnormalities, none of which led to permanent discontinuation of treatment. No evidence of renal impairment was found, it has however been demonstrated in the clinical trials with adalimumab.

The summary of product characteristics for both etanercept and adalimumab reports elevated liver enzymes during the treatment. In the aforementioned cohort, a significant rise in the mean ALT was demonstrated; however, these values did not exceed the upper limit of the normal reference range. The Italian PSOCARE registry found that that in patients treated with infliximab, it was associated with the risk of doubling the upper limit of aspartate aminotransferase (OR: 1.87) and ALT (OR: 1.74). No change in serum aspartate aminotransferase or ALT levels was seen in those treated with adalimumab or etanercept at baseline, weeks 8 or 16 during the treatment.

The BAD guidelines currently support the use of anti-nuclear antibody testing, which was observed in <4% of patients in the cohort study, with no patients developing clinical symptoms. Previous literature has shown, however, that seroconversion of anti-nuclear antibodies (ANA) during TNF inhibitor therapy can result in a lupus-like syndrome, the level of which can be reassessed if clinical symptoms develop. However, the evidence is poor and larger prospective studies are required.

No studies were found assessing laboratory testing and monitoring for patients with psoriasis treated with secukinumab or ustekinumab.

Guidelines for assessment and monitoring

The BAD, EADV, and AAD recommend undertaking a number of screening laboratory investigations at baseline and regular intervals throughout the treatment, which is supported by little or no evidence. There needs to be further larger prospective studies to provide further evidence about which laboratory testing is appropriate and at what intervals.

Pregnancy

Bogas and Leandro reviewed cases of biologic use in pregnancy for a variety of autoimmune conditions including plaque psoriasis. The review concluded that the lack of data was a significant limitation to drawing conclusions about the safety of TNF inhibitors in pregnancy, but that the risk appeared to be low, with no significant increase in congenital malformations or complications seen in comparison with rates in the general population. These findings are supported by a Spanish retrospective cohort study in IBD patients and in the study by Chambers and Johnson, which found no association between TNF inhibitors and unfavorable pregnancy outcomes.

In contrast, data from the British Society of Rheumatology and Biologics Registry have suggested an increased rate of early spontaneous miscarriage in patients taking TNF inhibitors, but results are confounded by concomitant methotrexate use and severity of rheumatological disease.

A total of 31 cases of pregnancy associated with maternal ustekinumab use have been found in pooled clinical trial data over a period of 4 years, with no incidence of fetal malformation or death reported.

As of yet, there is insufficient evidence of the safety profile for ustekinumab and secukinumab with which to draw conclusions about their use in pregnancy.

Guidelines for assessment and monitoring

BAD guidelines advise discontinuing TNF inhibitors in pregnancy, whereas guidance from the AAD does not offer a recommendation. European guidelines state that treatment with adalimumab and infliximab is absolutely contraindicated, whereas etanercept and ustekinumab are relatively contraindicated.

There is currently no conclusive evidence linking TNF inhibitors to maternal complications in pregnancy or congenital malformations, and EADV guidance recommends...
that, for those with severe psoriasis who require a systemic agent, etanercept should be regarded as first line where the benefit outweighs the risk.

Currently, in the UK, ciclosporin is the first-line systemic treatment over biologic therapy; however, given the accumulating evidence over the safety of TNF inhibitors in pregnancy, they may be recommended to be continued in the first and second trimesters on a case-by-case basis in future iterations of biologic therapy guidelines for psoriasis. Further results from observational registries in patients with psoriasis on biologic therapies will help clarify the risk of maternal and newborn complications.

Vaccinations
Given that biologic agents target the immune system, using all available approaches to prevent infection is vital. Current guidance from the AAD, EDAV, and BAD all recommend vaccination prior to the commencement of a systemic therapy if possible with pneumococcal, influenza, tetanus–diphtheria, and hepatitis A/B depending upon the local guidance. Hepatitis B vaccination is supported by the AAD and EADV only. Live vaccines including BCG vaccine, varicella-zoster virus, yellow fever, and measles-mumps-rubella vaccinations are contraindicated in patients treated with biologic agents. Currently, neither the EADV,
AAD, or BAD guidelines recommend prior vaccination with herpes zoster; however, a recent review that evaluated the risk of herpes zoster during the treatment with etanercept, adalimumab, infliximab, and ustekinumab in psoriasis and other inflammatory conditions found infliximab to be associated with an increased risk of herpes zoster, but the risk with the other biologics remains controversial, therefore vaccination should be considered.71

At present, no data have been published specific to patients with psoriasis. Data from other population groups, however, have demonstrated that the use of TNF-α inhibitors does not influence the effectiveness of vaccination against influenza A but may impair the immune response to influenza B and the pneumococcal vaccine. The immune response, however, in those receiving ustekinumab is not believed to be impaired.72,73

Given the current evidence and the increased theoretical risk of infection in those receiving treatment with a biologic, the consensus is the routine vaccination in line with local guidance with inactivated vaccines prior to the treatment and annual influenza during the treatment if required.

Conclusion

From this review of the current literature and guidelines, it is evident that there are areas of routine screening and monitoring, which are recommended in current practice, that are supported by limited evidence. It is, no doubt, difficult for professional bodies to make recommendations on the frequency screening and monitoring of low frequency of adverse events, when the data to underpin these recommendations are limited. Furthermore, clinicians need to consider the associated health care costs of routine testing and the risk of detecting false positives, leading to further investigation and morbidity. This highlights the need for evidence from real-world observational cohorts/registries to evaluate the true risk of various adverse events in those with psoriasis undergoing treatment with biologics.

Despite the various adverse events presented here, it is important to note that biologic therapies have a better and more well-defined safety profile than many alternative conventional systemic therapies for psoriasis and other autoimmune diseases.

This paper draws together evidence from major psoriasis biologic therapy guidelines as an accessible overall summary of how these drugs should be monitored (Figure 1). Given the gaps in knowledge which are currently undergoing investigation in various biologic registries around the world, it is likely that recommendations for assessment and monitoring of adverse events will also be updated based on better evidence accordingly in the near future.

Disclosure

The authors report no conflicts of interest in this work.

References


